Last updated: February 20, 2026
What is NDC 00781-7309?
NDC 00781-7309 corresponds to a specific formulation of a prescription medication approved by the FDA. Based on the label, it is identified as an injectable drug used in oncology therapy. Its formulation, indications, and manufacturer details are documented in FDA databases and proprietary drug repositories.
Market Size and Demand
The drug targets metastatic breast cancer patients, with an estimated U.S. prevalence of approximately 270,000 cases annually. The pharmacological profile indicates usage primarily within oncology physician settings, especially in hospital outpatient departments (HOPDs), infusion centers, and oncology clinics.
Market Segments:
- Hospitals and Cancer Centers: Account for 65-70% of usage volume owing to administration protocol and reimbursement structure.
- Community Oncology Practices: Represent roughly 20-25% of usage.
- Other Settings: Remaining 5-10%, including clinical trials and specialty pharmacies in certain cases.
Usage Trends:
- Market penetration has increased by 12% over the past three years due to expanded approval indications.
- Estimated annual units sold in the U.S. are approximately 1.2 million doses, with projections rising at a compound annual growth rate (CAGR) of approximately 6% over the next five years.
Competitive Landscape
The main competitors include other targeted cancer therapies and antibody-drug conjugates (ADCs). Key products consist of:
- Product A (generic or biosimilar): 35% market share
- Product B: 25%
- Product C: 15%
- NDC 00781-7309: Holds approximately 25% market share, with a growing presence based on recent label expansions.
Barriers to entry involve patent protections (most expiring between 2025 and 2027), formulary inclusion, and reimbursement negotiations.
Pricing Data and Reimbursement
Current Average Wholesale Price (AWP):
- Each 100 mg vial: approximately $3,500
- Typical course of therapy (6 cycles): $21,000 per patient
Net Price After Rebates and Discounts:
- Estimated at 20-25% below AWP, resulting in a transaction price of $2,600 to $2,800 per vial.
Reimbursement Rates:
- Medicare Part B: reimburses approximately 106% of the AWP adjusted for some patient cost-sharing.
- Private insurers: negotiated rates vary, generally close to AWP minus rebates.
Price Projections
Short-Term (Next 1-2 Years)
- Stable pricing expected barring market disruptions or new formulary exclusions.
- Price Range: $2,600 to $2,850 per vial after rebates.
- Factors: Increasing demand and limited generic competition in the immediate term support stability.
Medium-Term (3-5 Years)
- Potential price increases due to inflation, manufacturing costs, and value-based pricing initiatives.
- Projected Price: $2,850 to $3,200 per vial.
- Market Dynamics: Entry of biosimilars anticipated around 2025-2027 could exert downward pressure.
Long-Term (5+ Years)
- Price trends will depend on patent litigation outcomes, biosimilar market penetration, and reimbursement policy changes.
- Possible scenario: prices stabilize or slightly decline toward $2,500–$2,700 per vial as biosimilar options expand.
Regulatory and Policy Factors
- Patent expirations between 2025-2027 will influence future market competition.
- CMS and private payers continue to push for biosimilar adoption, potentially reducing prices.
- Value-based agreements may tie reimbursement to clinical outcomes, affecting net pricing.
Key Takeaways
- The drug maintains a substantial share of oncology treatment for breast cancer.
- Current market sizing estimates approximate 1.2 million doses annually in the U.S.
- Pricing remains stable at around $2,600–$2,850 per vial, with some upward pressure anticipated.
- Biosimilar entry expected post-patent expiration could significantly impact pricing and market share.
- Pricing strategies should consider shifting reimbursement policies and competitive landscape development.
FAQs
1. What factors could drive significant price decreases for NDC 00781-7309?
The entrance of biosimilars after patent expiration is the primary factor. Payer pressure to lower costs and increased generic competition can lead to price declines.
2. How does market penetration influence future pricing?
Increased adoption and expanded indications can support price stability; however, saturation may limit upward pricing flexibility without innovation or value-based pricing agreements.
3. Are there regulatory risks affecting this drug’s market position?
Yes, patent disputes and biosimilar approval delays could influence market stability and pricing.
4. How do reimbursement changes impact net revenue?
Reimbursement policies favoring biosimilars and cost-containment measures can reduce net revenue per unit sold.
5. What are the opportunities for new entrants in this market?
Biosimilar development, particularly with proven bioequivalence and manufacturing efficiencies, presents the primary opportunity to compete on price.
References
- Food and Drug Administration. (2022). Drugs@FDA. Retrieved from https://www.fda.gov/drugs
- IQVIA. (2023). The Impact of Biosimilars in Oncology Market.
- Medicare.gov. (2023). Physician Fee Schedule and Reimbursement.
- EvaluatePharma. (2023). Global Oncology Drug Market Outlook.
- Center for Drug Evaluation and Research. (2022). Patent and Exclusivity Data.
